These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 24976875)

  • 1. Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities.
    Tilakaratne A; Soory M
    Open Dent J; 2014; 8():109-24. PubMed ID: 24976875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation.
    Gu Y; Lee HM; Sorsa T; Salminen A; Ryan ME; Slepian MJ; Golub LM
    Pharmacol Res; 2011 Dec; 64(6):573-9. PubMed ID: 21771657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines.
    Ramamurthy NS; Rifkin BR; Greenwald RA; Xu JW; Liu Y; Turner G; Golub LM; Vernillo AT
    J Periodontol; 2002 Jul; 73(7):726-34. PubMed ID: 12146531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease.
    Federici TJ
    Pharmacol Res; 2011 Dec; 64(6):614-23. PubMed ID: 21843641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases.
    El-Shinnawi U; Soory M
    Endocr Metab Immune Disord Drug Targets; 2015; 15(4):261-76. PubMed ID: 25922082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemically modified tetracyclines: Novel therapeutic agents in the management of chronic periodontitis.
    Agnihotri R; Gaur S
    Indian J Pharmacol; 2012 Mar; 44(2):161-7. PubMed ID: 22529468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review.
    Reddy MS; Geurs NC; Gunsolley JC
    Ann Periodontol; 2003 Dec; 8(1):12-37. PubMed ID: 14971246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role for non-antimicrobial actions of tetracyclines in combating oxidative stress in periodontal and metabolic diseases: a literature review.
    Soory M
    Open Dent J; 2008; 2():5-12. PubMed ID: 19088876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs.
    Rifkin BR; Vernillo AT; Golub LM
    J Periodontol; 1993 Aug; 64(8 Suppl):819-27. PubMed ID: 8410621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical applications of non-antimicrobial tetracyclines in dermatology.
    Monk E; Shalita A; Siegel DM
    Pharmacol Res; 2011 Feb; 63(2):130-45. PubMed ID: 20937386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetracyclines: nonantibiotic properties and their clinical implications.
    Sapadin AN; Fleischmajer R
    J Am Acad Dermatol; 2006 Feb; 54(2):258-65. PubMed ID: 16443056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemically modified tetracyclines an emerging host modulator in chronic periodontitis patients: A randomized, double-blind, placebo-controlled, clinical trial.
    Alyousef AA; Divakar DD; Muzaheed
    Microb Pathog; 2017 Sep; 110():279-284. PubMed ID: 28687322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking Periodontal Disease Progression by Inhibiting Tissue-Destructive Enzymes: A Potential Therapeutic Role for Tetracyclines and Their Chemically-Modified Analogs.
    Rifkin BR; Vernillo AT; Golub LM
    J Periodontol; 1993 Aug; 64 Suppl 8S():819-827. PubMed ID: 29539753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minocycline: far beyond an antibiotic.
    Garrido-Mesa N; Zarzuelo A; Gálvez J
    Br J Pharmacol; 2013 May; 169(2):337-52. PubMed ID: 23441623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs.
    Golub LM; Ramamurthy NS; McNamara TF; Greenwald RA; Rifkin BR
    Crit Rev Oral Biol Med; 1991; 2(3):297-321. PubMed ID: 1654139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Chemically Modified Tetracyclines in the Management of Periodontal Diseases: A Review.
    Ghangurde AA; Ganji KK; Bhongade ML; Sehdev B
    Drug Res (Stuttg); 2017 May; 67(5):258-265. PubMed ID: 28268238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-antimicrobial properties of tetracyclines--dental and medical implications.
    Rawal SY; Rawal YB
    West Indian Med J; 2001 Jun; 50(2):105-8. PubMed ID: 11677904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tetracyclines on bone metabolism.
    Vernillo AT; Rifkin BR
    Adv Dent Res; 1998 Nov; 12(2):56-62. PubMed ID: 9972123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-induced periodontal breakdown in rats.
    Llavaneras A; Ramamurthy NS; Heikkilä P; Teronen O; Salo T; Rifkin BR; Ryan ME; Golub LM; Sorsa T
    J Periodontol; 2001 Aug; 72(8):1069-77. PubMed ID: 11525440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory mechanisms and redox status in periodontal and cardiometabolic diseases: effects of adjunctive nutritional antioxidants and statins.
    Soory M
    Infect Disord Drug Targets; 2012 Aug; 12(4):301-15. PubMed ID: 22697128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.